BACKGROUND—In the Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced …

Background—In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and …

We thank Drs Replogle and Pittman for their comments on how to best report and refer to the
results of prospective, randomized, clinical trials. The Apixaban for Reduction in Stroke and …

2164 Circulation June 4, 2013 of predicted cTTR, 8 the benefit of apixaban was greatest at
centers with the lowest predicted TTR. However, the rate of major bleeding appeared to be …

Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …

Primary Objective: To determine if apixaban is noninferior to warfarin (INR target range 2.0-
3.0) in the combined endpoint of stroke (ischemic or hemorrhagic or of unspecified type) and …

Background A novel approach to determine the effect of a treatment is to calculate the delay
of event, which estimates the gain of event-free time. The aim of this study was to estimate …

Purpose: Perceived risk of bleeding is an obstacle to the use of oral anticoagulation in East
Asia. The effectiveness and risk of bleeding with new oral anticoagulants in East Asian …

Background The CHADS2 and HASBLED scores are important tools to predict the risks of
stroke and bleeding, respectively, in patients with atrial fibrillation (AF) and to help guide …